Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.
Existing drug may be effective in treating SARS-CoV-2
Scientists from the University of Chicago have found that the drug masitinib may be effective in treating COVID-19.
The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads.
X-ray crystallography gave us a strong indication of how this drug works, and we became confident that it has a chance to work in humans.
Nir Drayman, University of Chicago
Masitinib Inhibits the Replication of SARS-CoV-2 in Preclinical Models technologynetworks.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from technologynetworks.com Daily Mail and Mail on Sunday newspapers.
Scientists identify existing drugs that may inhibit SARS-CoV-2 virus
The COVID-19 pandemic has caused more than 600,000 deaths in the United States since the start of 2020 and more than 4 million globally. The search for effective treatments against the disease are ongoing, and one hurdle is that SARS-CoV-2, the virus that causes COVID-19, has a number of tricks up its molecular sleeve when it comes to infecting people.
In a recent study published in Nature Communications Biology, researchers from the U.S. Department of Energy s (DOE) Argonne National Laboratory and the University of Chicago identified a way to interfere with a sneaky mechanism the virus uses to prevent a response from an infected person s immune system.
University recognizes spring Employees of the Month | The University of Kansas ku.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ku.edu Daily Mail and Mail on Sunday newspapers.